Skip to main content

Table 2 Protocol of LCH-GZWC-2018 (Wang)

From: Exploration of treatment in childhood Langerhans cell histiocytosis based on inflammatory and malignant symptoms: a pilot study

Group A

Initial treatment(duration of 6 weeks)

  VDS

3 mg/m 2

IV

D1 D8 D15 D22 D29 D36

  PSL

2 mg/kg

oral

D1-D28, D29-42 weekly tapering

Maintenance treatment(duration of 12 months)

  VDS

3 mg/m 2

IV

once per 3 weeks

  PSL

2 mg/kg

oral

5 days per 3 weeks

Group B

Initial treatment(duration of 6 weeks)

  VDS

3 mg/m 2

IV

D1 D8 D15 D22 D29 D36

  PSL

2 mg/kg

oral

D1-D28, D29-42 weekly tapering

  THP

20 mg/m 2

IV

D1 D15 D29

  CTX

10 mg/kg

IV

D1-5 D15-19 D29-33

  MTXa

25 mg/m 2

oral

once per week

  Vemur#

15-20 mg/kg

oral

twice per day

Maintenance treatment(duration of 12 months)

  VDS

3 mg/m 2

IV

once per 3 weeks

  PSL

2 mg/kg

oral

5 days per 3 weeks

  THP

20 mg/m 2

IV

once per 6 weeks (W1, W7, W13,W19)

  CTX

10 mg/kg

IV

once per 6 weeks (W4, W10, W16,W22)

  6MP

50 mg/m 2

oral

once per day

  MTXa

25 mg/m 2

oral

once per week

  Vemur#

15-20 mg/kg

oral

twice per day

  1. VDS Vindesine, IV Intravenous, PSL Methylprednisolone, THP Pirarubicin, CTX Cyclophosphamide, MTX Methotrexate, Vemur Vemurafenib, 6MP 6mercaptopurine
  2. aAdditional use when inflammatory symptoms do not improve; #Additional use when tumor symptoms do not improve